Emily Kaiser Maharjan, Assistant Managing Editor

With the acquisition, Topcon Healthcare also assumes RetInSight’s AI algorithms that analyze retinal images to detect and monitor disease.

While the study included a range of subjects in a variety of stages of presbyopia, the change in crystalline lens geometry and anterior segment was most pronounced in emmetropic and myopic presbyopes.

Results from the first-in-human study of SpyGlass Pharma's bimatoprost-eluting IOL showed significant reduction in IOP and improved best-corrected distance visual acuity.

An emerging treatment approach for a commonly underdiagnosed ocular surface disease.

At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.

Eva Kim, MD, offers valuable insights into why EVO ICL is becoming a compelling alternative to traditional corneal procedures like LASIK.

In honor of the Myopia Management Navigator’s 1-year anniversary, Dr Tucker shares clinical insights, practical tips, and business opportunities for optometrists looking to expand their scope and elevate patient care through evidence-based myopia management.

Elise Kramer, OD, FAAO, FSLS, describes how she uses myriad tools to help her patients with dry eye manage the condition, especially in conjunction with contact lenses.

According to a press release, Myatro XL is the first 0.05% atropine eye drop for pediatric myopia control. It will be commercially available in India in July 2025.

The starry faculty has a galaxy of symposia planned for May 4, 2025.

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, lectured on retinal updates at CRU 2025. The pair also covered the power of a low vision referral for patients with retinal disease.

Following a discussion on low-dose atropine, Paul Karpecki, OD, FAAO, shares his views on what the future of myopia management looks like.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Dr Rachelle Lin highlights the urgent need for early intervention in childhood myopia, discusses associated retinal and systemic risks, and emphasizes the long-term impact of axial length control in reducing serious ocular complications.

Paul Karpecki, OD, FAAO, sits down to discuss Sydnexis's atropine formulation and what an FDA approval would mean for myopia management.

Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.

VEVYE Access for All aims to reduce barriers to dry eye disease therapy via a partnership with PhilRx.

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Discover a unique blend of cutting-edge eye care education and world-class wine tasting at the CRU Eye Symposium in Napa Valley, where learning meets luxury in an intimate setting.

Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.

The gel was investigated in a case series, which was presented in a poster at SECO 2025.

Julie Rodman, OD, MS, FAAO, sits down with Optometry Times to discuss her anticipation for the future of technology in optometry, especially retinal care.

Ahead of her SECO presentations, Julie Rodman, OD, MS, FAAO, shares some tidbits of what attendees can expect.

Systane PRO preservative-free is the longest lasting dry eye drop in the Systane portfolio, according to Alcon.